Evidence map›Paper›PMID 41427729›Full record

ArticleJournal of neurochemistry2025

Oral KDS2010, a Monoamine Oxidase-B (MAO-B) Inhibitor, Slows the Deterioration of Motor Coordination in Genetic SCA1 Models by Inhibiting Astrocytic MAO-B-Mediated Inflammation.

Dong Ho Woo, Ju-Hyun Jeon, Hye-Jin Ryu, Gyeong Min Lee, Hye-Won Lim, Ki Duk Park, Kwang Lae Hoe, Sang Dal Rhee

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of neurochemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Dong Ho WooCenter for Global Biopharmaceutical Research, Korea Institute of Toxicology, Daejeon, South Korea.ORCID 0000-0003-3366-3831
Ju-Hyun JeonCenter for the Rare Disease Therapeutic Technology, Korea Research Institute of Chemical Technology, Daejeon, South Korea.
Hye-Jin RyuCenter for the Rare Disease Therapeutic Technology, Korea Research Institute of Chemical Technology, Daejeon, South Korea.
Gyeong Min LeeCenter for the Rare Disease Therapeutic Technology, Korea Research Institute of Chemical Technology, Daejeon, South Korea.
Hye-Won LimCenter for Global Biopharmaceutical Research, Korea Institute of Toxicology, Daejeon, South Korea.
Ki Duk ParkBrain Science Institute, Korea Institute of Science and Technology (KIST), Seoul, South Korea.
Kwang Lae HoeGraduate School of New Drug Discovery and Development, Chungnam National University, Daejeon, South Korea.
Sang Dal RheeCenter for the Rare Disease Therapeutic Technology, Korea Research Institute of Chemical Technology, Daejeon, South Korea.

Funding

Ministry of Science and ICT, South Korea 1711198445Ministry of Science and ICT, South Korea 2710008773Ministry of Science and ICT, South Korea KK2331-10Ministry of Science and ICT, South Korea KK-2410
6 · The paper itself

Abstract

Spinocerebellar ataxia type 1 (SCA1) is an autosomal dominant neurodegenerative disorder characterized by balance and gait disturbance, muscle coordination deficits, and dysarthria as a primary symptom. SCA1 is caused by the expansion of CAG repeats in the ATXN1 gene, leading to a polyglutamine(polyQ) tract in the Ataxin-1 protein. In this study, the effects of KDS2010, an inhibitor of monoamine oxidase-B (MAO-B), were evaluated in a transgenic mouse model of SCA1 (SCA1

Indexed as

AstrocytesMonoamine OxidaseMonoamine Oxidase InhibitorsSpinocerebellar AtaxiasAdministration, OralAnimalsAtaxin-1Disease Models, AnimalFemaleInflammationMaleMiceMice, Inbred C57BLMice, TransgenicMotor ActivityAtaxin-1Monoamine OxidaseMonoamine Oxidase InhibitorsGFAPKDS2010MAO‐BSCA1

Identifiers

PMID41427729
PMCPMC12721003

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.